CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis-Reference-Cited by-同舟云学术

CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis

Published:2006-05-21 Issue:6 Volume:12 Page:671-676
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Teixeira-Clerc Fatima,Julien Boris,Grenard Pascale,Van Nhieu Jeanne Tran,Deveaux Vanessa,Li Liying,Serriere-Lanneau Valérie,Ledent Catherine,Mallat Ariane,Lotersztajn Sophie

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm1421.pdf

Reference32 articles.

1. Lotersztajn, S., Julien, B., Teixeira-Clerc, F., Grenard, P. & Mallat, A. Hepatic fibrosis: molecular mechanisms and drug targets. Annu. Rev. Pharmacol. Toxicol. 45, 605–628 (2005).

2. Julien, B. et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 128, 742–755 (2005).

3. Hezode, C. et al. Daily cannabis smoking as a risk factor for fibrosis progression in chronic hepatitis C. Hepatology 42, 63–71 (2005).

4. Pertwee, R.G. Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. 6, 635–664 (1999).

5. Di Marzo, V., Bifulco, M. & De Petrocellis, L. The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discov. 3, 771–784 (2004).

Cited by 467 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Key regulators of hepatic stellate cell activation in alcohol liver Disease: A comprehensive review;International Immunopharmacology;2024-11

2. The molecular signature of the peripheral cannabinoid receptor 1 antagonist AM6545 in adipose, liver and muscle tissue;Toxicology and Applied Pharmacology;2024-10

3. Preclinical human and murine models of hepatocellular carcinoma (HCC);Clinics and Research in Hepatology and Gastroenterology;2024-08

4. G protein-coupled receptors and traditional Chinese medicine: new thinks for the development of traditional Chinese medicine;Chinese Medicine;2024-07-02

5. Peripherally Restricted CB1 Receptor Inverse Agonist JD5037 Treatment Exacerbates Liver Injury in MDR2-Deficient Mice;Cells;2024-06-25